PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer
-
Published:2023-01
Issue:
Volume:178
Page:139-149
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Saw Stephanie P.L., Ng Win Pin, Zhou Siqin, Lai Gillianne G.Y.ORCID, Tan Aaron C.ORCID, Ang Mei-Kim, Lim Wan-TeckORCID, Kanesvaran Ravindran, Ng Quan Sing, Jain Amit, Tan Wan Ling, Rajasekaran Tanujaa, Chan Johan W.K., Teh Yi LinORCID, Pang Mengyuan, Yeo Jia-Chi, Takano AngelaORCID, Ong Boon-HeanORCID, Tan Eng-Huat, Tan Sze HueyORCID, Skanderup Anders J., Tan Daniel S.W.ORCID
Subject
Cancer Research,Oncology
Reference26 articles.
1. Osimertinib in resected EGFR-mutated non–small-cell lung cancer;Wu;N Engl J Med [Internet],2020 2. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial;Felip;The Lancet,2021 3. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial;O'Brien;Lancet Oncol,2022 4. Association of clinicopathologic and molecular tumor features with recurrence in resected early-stage epidermal growth factor receptor–positive non–small cell lung cancer;Saw;JAMA Netw Open,2021 5. PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis;Zhou;Transl Lung Cancer Res,2015
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|